Want to see IN:MEDICAMEQ full AI Analyst Report?
Top Page
Medicamen Biotech Limited
(MEDICAMEQ)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹268.00
▼(-26.96% Downside)
Action:Reiterated
Date:09/17/26
The score is held back primarily by weak cash-flow quality (multi-year negative operating/free cash flow) and a relatively expensive valuation (high P/E, low yield). These are partially offset by a conservative balance sheet and strong technical momentum with the stock trading well above key moving averages.
Positive Factors
Recent Revenue Growth
The return to strong revenue growth in FY2026 indicates that demand and sales execution can recover after a weaker year. If sustained, higher volumes can improve operating leverage, support investment in the formulations portfolio, and strengthen the company’s earnings base over the next several quarters.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow means reported earnings are not translating into liquidity. Continued cash shortfalls can increase dependence on working-capital funding or external financing, reducing flexibility to invest and making financial performance less durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Recent Revenue Growth
The return to strong revenue growth in FY2026 indicates that demand and sales execution can recover after a weaker year. If sustained, higher volumes can improve operating leverage, support investment in the formulations portfolio, and strengthen the company’s earnings base over the next several quarters.
Read all positive factors
Medicamen Biotech Limited (MEDICAMEQ) vs. iShares MSCI India ETF (INDA)
Market Cap
₹3.47B
Dividend Yield0.39%
Average Volume (3M)2.26K
Price to Earnings (P/E)32.0
Beta (1Y)1.07
Revenue Growth24.66%
EPS Growth10.89%
CountryIN
Employees405
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)8.01
Shares Outstanding13,562,815
10 Day Avg. Volume1,203
30 Day Avg. Volume2,264
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)1.08
Price to Sales (P/S)1.51
P/FCF Ratio-7.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medicamen Biotech Limited Business Overview & Revenue Model
Company Description
Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompass...
How the Company Makes Money
Medicamen Biotech Limited makes money primarily by manufacturing and selling pharmaceutical formulations (generic finished-dosage medicines). Its revenue is generated from (1) domestic sales in India, where it supplies medicines through marketing/...
Medicamen Biotech Limited Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
78
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.03B | 1.98B | 1.63B | 1.79B | 1.41B | 1.15B |
| Gross Profit | 593.22M | 540.86M | 389.90M | 852.01M | 687.74M | 479.88M |
| EBITDA | 214.06M | 227.00M | 201.02M | 245.66M | 239.99M | 258.07M |
| Net Income | 108.29M | 96.41M | 71.08M | 109.31M | 148.44M | 148.98M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.72B | 2.97B | 2.95B | 2.79B | 2.26B |
| Cash, Cash Equivalents and Short-Term Investments | 312.64M | 312.64M | 37.59M | 147.86M | 207.79M | 38.25M |
| Total Debt | 0.00 | 477.84M | 332.53M | 311.12M | 257.09M | 257.96M |
| Total Liabilities | -2.76B | 964.38M | 841.04M | 875.67M | 851.03M | 792.24M |
| Stockholders Equity | 2.76B | 2.76B | 2.13B | 2.07B | 1.93B | 1.46B |
Cash Flow | ||||||
| Free Cash Flow | -145.81M | -397.08M | -119.32M | -130.31M | -128.94M | -44.99M |
| Operating Cash Flow | -124.06M | -349.31M | -98.59M | -67.44M | -62.93M | 41.09M |
| Investing Cash Flow | -15.21M | -47.78M | -23.78M | -55.63M | -58.80M | -84.73M |
| Financing Cash Flow | 538.49M | 672.13M | 12.16M | 63.13M | 291.27M | 42.98M |
Medicamen Biotech Limited Technical Analysis
Negative
366.90
Price Trends
286.96
Negative
262.52
Negative
278.21
Negative
Market Momentum
-11.11
Positive
37.85
Neutral
19.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICAMEQ, the sentiment is Negative. The current price of 366.9 is above the 20-day moving average (MA) of 286.02, above the 50-day MA of 286.96, and above the 200-day MA of 278.21, indicating a bearish trend. The MACD of -11.11 indicates Positive momentum. The RSI at 37.85 is Neutral, neither overbought nor oversold. The STOCH value of 19.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICAMEQ.
Medicamen Biotech Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₹3.47B | 31.99 | ― | 0.39% | 24.66% | 10.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.35B | 19.29 | ― | 0.65% | 11.43% | 258.53% | |
54 Neutral | ₹10.60B | 136.14 | ― | 1.93% | -3.14% | -5.80% | |
52 Neutral | ₹1.55B | 11.14 | ― | ― | 49.96% | 33.70% | |
50 Neutral | ₹6.95B | 43.53 | ― | ― | 89.64% | 10627.64% | |
48 Neutral | ₹2.00B | -0.90 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:MEDICAMEQ
Medicamen Biotech Limited
255.50
-120.56
-32.06%
IN:ALBERTDAVD
Albert David Ltd
762.90
-114.67
-13.07%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
447.90
285.75
176.23%
IN:MEDICO
Medico Remedies Ltd.
18.65
-31.30
-62.66%
IN:NECLIFE
Nectar Lifesciences Ltd.
10.29
-4.61
-30.94%
IN:VALIANTLAB
Valiant Laboratories Ltd.
127.90
44.90
54.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.